Cargando…

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae

BACKGROUND: Urinary tract infections (UTIs) caused by extended spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) pose a significant challenge due to limited treatment options. The objective of this study was to compare outcomes in patients treated with standard IV therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefler, Jade L, Perez, Katherine K, Musick, William L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809623/
http://dx.doi.org/10.1093/ofid/ofz360.1939
_version_ 1783462034925420544
author Hefler, Jade L
Perez, Katherine K
Musick, William L
author_facet Hefler, Jade L
Perez, Katherine K
Musick, William L
author_sort Hefler, Jade L
collection PubMed
description BACKGROUND: Urinary tract infections (UTIs) caused by extended spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) pose a significant challenge due to limited treatment options. The objective of this study was to compare outcomes in patients treated with standard IV therapy or oral fosfomycin for ESBL and CRE UTIs. METHODS: Retrospective cohort review of inpatients diagnosed with ESBL and CRE UTIs between June 2016 and September 2017 at a seven-hospital system. Patients with polymicrobial UTI, bloodstream infections, additional anatomical site with ESBL/CRE, or those requiring renal replacement therapy were excluded. Only patients with documented fosfomycin susceptible isolates in vitro were included. Eligible patients were divided into two groups: standard IV therapy (SDTx) or fosfomycin therapy (FOS). FOS group could receive ≤72 hours of other active antibiotics from urine culture collection (UTI onset) to the first dose of fosfomycin. Quick sequential organ failure assessment (qSOFA) scores were calculated at UTI onset. The primary endpoint was functional cure defined as resolution of symptoms without microbiological failure. Microbiological failure was defined as a positive urine culture within the index hospitalization or 30 days. RESULTS: There were 70 patients included: 31 treated with SDTx and 39 with FOS. ESBL Echerichia coli was most common, accounting for 58% of UTIs in SDTx and 71.8% in FOS. ESBLs accounted for 71% (n = 22/31) of UTIs in SDTx and 89.7% (n = 35/39) in FOS. The overall qSOFA score was 0.7 (range, 0–3) with the majority of patients scoring < 2 (80.6% in SDTx vs. 92.3% in FOS; P = 0.29). There was no significant difference in functional cure rate (n = 30, 96.8% SDTx vs. n = 37, 94.9% FOS; P = 0.83). SDTx patients had a longer length of stay (15.3 days vs. 7.3 days with FOS; P = 0.04), duration of active therapy (7.6 days vs. 3 days with FOS; P < 0.0001), and time from UTI onset to discharge (10.3 days vs. 6.6 days with FOS; P = 0.002). There were no adverse drug events reported. CONCLUSION: Oral fosfomycin was a safe and effective alternative to standard IV therapy for ESBL and CRE UTIs in this investigation and demonstrated similar functional cure rates. Additionally, patients treated with fosfomycin had shorter hospitalizations and durations of antibiotic therapy. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809623
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68096232019-10-28 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae Hefler, Jade L Perez, Katherine K Musick, William L Open Forum Infect Dis Abstracts BACKGROUND: Urinary tract infections (UTIs) caused by extended spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) pose a significant challenge due to limited treatment options. The objective of this study was to compare outcomes in patients treated with standard IV therapy or oral fosfomycin for ESBL and CRE UTIs. METHODS: Retrospective cohort review of inpatients diagnosed with ESBL and CRE UTIs between June 2016 and September 2017 at a seven-hospital system. Patients with polymicrobial UTI, bloodstream infections, additional anatomical site with ESBL/CRE, or those requiring renal replacement therapy were excluded. Only patients with documented fosfomycin susceptible isolates in vitro were included. Eligible patients were divided into two groups: standard IV therapy (SDTx) or fosfomycin therapy (FOS). FOS group could receive ≤72 hours of other active antibiotics from urine culture collection (UTI onset) to the first dose of fosfomycin. Quick sequential organ failure assessment (qSOFA) scores were calculated at UTI onset. The primary endpoint was functional cure defined as resolution of symptoms without microbiological failure. Microbiological failure was defined as a positive urine culture within the index hospitalization or 30 days. RESULTS: There were 70 patients included: 31 treated with SDTx and 39 with FOS. ESBL Echerichia coli was most common, accounting for 58% of UTIs in SDTx and 71.8% in FOS. ESBLs accounted for 71% (n = 22/31) of UTIs in SDTx and 89.7% (n = 35/39) in FOS. The overall qSOFA score was 0.7 (range, 0–3) with the majority of patients scoring < 2 (80.6% in SDTx vs. 92.3% in FOS; P = 0.29). There was no significant difference in functional cure rate (n = 30, 96.8% SDTx vs. n = 37, 94.9% FOS; P = 0.83). SDTx patients had a longer length of stay (15.3 days vs. 7.3 days with FOS; P = 0.04), duration of active therapy (7.6 days vs. 3 days with FOS; P < 0.0001), and time from UTI onset to discharge (10.3 days vs. 6.6 days with FOS; P = 0.002). There were no adverse drug events reported. CONCLUSION: Oral fosfomycin was a safe and effective alternative to standard IV therapy for ESBL and CRE UTIs in this investigation and demonstrated similar functional cure rates. Additionally, patients treated with fosfomycin had shorter hospitalizations and durations of antibiotic therapy. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809623/ http://dx.doi.org/10.1093/ofid/ofz360.1939 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hefler, Jade L
Perez, Katherine K
Musick, William L
2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title_full 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title_fullStr 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title_full_unstemmed 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title_short 2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
title_sort 2261. oral fosfomycin for treatment of urinary tract infections due to extended-spectrum β-lactamase and carbapenem-resistant enterobacteriaceae
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809623/
http://dx.doi.org/10.1093/ofid/ofz360.1939
work_keys_str_mv AT heflerjadel 2261oralfosfomycinfortreatmentofurinarytractinfectionsduetoextendedspectrumblactamaseandcarbapenemresistantenterobacteriaceae
AT perezkatherinek 2261oralfosfomycinfortreatmentofurinarytractinfectionsduetoextendedspectrumblactamaseandcarbapenemresistantenterobacteriaceae
AT musickwilliaml 2261oralfosfomycinfortreatmentofurinarytractinfectionsduetoextendedspectrumblactamaseandcarbapenemresistantenterobacteriaceae